VolitionRX Limited - VNRX STOCK NEWS

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the closing of its underwritten public offering of 3,809,524 shares, raising approximately $20 million before expenses. All shares were sold by Volition, and the underwriter has an option to purchase an additional 571,428 shares. The funds will be used for general corporate purposes, including product development and potential acquisitions. The offering was conducted under a previously filed shelf registration statement with the SEC.

VolitionRx Limited (NYSE AMERICAN: VNRX) announced a public offering of 3,809,524 shares of common stock, priced to generate approximately $20 million in gross proceeds. The offering is expected to close on February 12, 2021, pending customary conditions. Cantor Fitzgerald & Co. is managing the offering, which includes an option for the underwriter to purchase an additional 571,428 shares. Net proceeds will fund general corporate purposes, including product development and potential acquisitions. The last reported share price was $6.27.

VolitionRx Limited (NYSE AMERICAN: VNRX) has announced an underwritten public offering of its common stock, with all shares to be sold by the company. The offering is subject to customary closing conditions and includes a 30-day option for the underwriter to purchase an additional 15% of shares. The offering is conducted under an effective shelf registration statement filed with the SEC. This is part of Volition's strategy to fund its diagnostic products based on the Nucleosomics™ platform, aimed at early disease detection and diagnosis.

VolitionRx Limited (NYSE AMERICAN: VNRX) has announced key management appointments aimed at driving commercialization efforts. Terig Hughes is appointed Chief Financial Officer, alongside Gaetan Michel as Chief Operating Officer, Gael Forterre as Chief Commercial Officer, and Mark Eccleston as Chief Technology Officer. The company has opened a new manufacturing facility and secured approximately $4 million in non-dilutive funding. The leadership transitions come as VolitionRx shifts from R&D to a focus on market readiness for its cancer diagnostic products.

VolitionRx Limited (NYSE AMERICAN: VNRX) will be presenting live at VirtualInvestorConferences.com on February 4, 2021, at 12:00 PM EST. The session, led by Scott Powell, CFO, aims to engage investors with real-time Q&A opportunities. VolitionRx specializes in epigenetic blood tests to aid in diagnosing various cancers and diseases, utilizing Nucleosomics technology. Participants are encouraged to pre-register and check their systems to ensure smooth access. An archived version will be available post-event for those unable to attend live.

VolitionRx Limited (NYSE AMERICAN: VNRX) presented an abstract at the virtual WCLC lung cancer conference, showcasing Nu.Q™ assays' potential in diagnosing lung cancer. The interim analysis indicates that these assays can reduce unnecessary biopsies by 32% for non-cancerous nodules detected via low-dose computed tomography (LDCT). The study, led by Professor Chen Jin-Shing at National Taiwan University Hospital, involves 1,200 subjects and aims to differentiate between benign nodules and early-stage lung cancers. Results will be published later this year.

VolitionRx Limited (NYSE AMERICAN: VNRX) has announced the opening of its new 10,000 square foot manufacturing facility, "Silver One," in Isnes, Belgium. This facility will enable Volition to produce critical raw materials and finished products, including the recently launched Nu.Q™ Vet Cancer Screening Test and a CE-marked blood cancer test. The investment of just over $1 million was mostly funded through non-dilutive sources. The new site aims to secure the supply chain and lower production costs, enhancing profitability.

VolitionRx Limited (NYSE AMERICAN: VNRX) has secured an additional $4 million in non-dilutive funding from the Walloon Region and Namur Invest in Belgium, bringing the total to approximately $15 million. The latest funding includes a $1.3 million grant and $2.7 million in loans, which will support various projects, including a new production facility and cancer-related research. CEO Cameron Reynolds expressed satisfaction with this development, highlighting its importance for ongoing projects and operations.

VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed Dr. Tom Butera DVM to its Board of Directors effective December 1, 2020. Dr. Butera, an experienced healthcare leader, will serve on the Audit, Compensation, and Nominations and Governance Committees. His appointment coincides with the recent launch of Volition's Nu.Q™ Vet Cancer Screening Test, which aims to enhance cancer diagnostics in both humans and animals. The company focuses on developing cost-effective blood tests through its proprietary Nucleosomics™ technology, with R&D activities in Belgium and additional locations globally.